CEO, CMO, Founder
Pierre Vandepapelière has been Amyl's co-founder, CEO, and CMO since 2020. Previously, he was CEO of Imcyse from 2014 to 2019, transforming the company into a rapidly growing biotech and raising €35M in Series B funding. During the COVID-19 pandemic, he contributed to several vaccine projects, including creating Astrivax. Pierre has also held leadership roles at Neovacs and GlaxoSmithKline. He holds a medical degree and a PhD. In his spare time, Pierre enjoys sailing, photography, and birdwatching.
CSO
Before joining Amyl, Damien worked as a Project Lead at Pharnext, focusing on neurodegenerative diseases, including Parkinson’s, Alzheimer’s, and ALS. He co-founded and served as CSO of Encefa for eight years, leading the development of a monoclonal anti-CD38 antibody for ALS. Damien holds an MSc in Biochemistry and Genetics from Agrocampus Rennes and a PhD in Neurosciences from Paris Sorbonne. He is currently the CSO of Amyl. Damien is also a fan of hard rock and metal music.
RD Director
Julie Goemaere joined Amyl Therapeutics as Director of Research and Development in early 2023. She has over 10 years of experience in scientific and management roles in the biotech sector. After her thesis on oxidative stress and neurodegeneration, she developed bioassays at GSK Vaccines and became a project manager focused on clinical research disclosure. At Thermo Fisher Scientific, she led upstream process development for viral vectors in gene therapy. Julie holds a PhD in Biological Sciences from UCLouvain, Belgium. In her current role, Julie is leading the R&D team with fervor, while in her private life, she likes to unwind in close contact with nature.
CFO, Legal and Financial Support
Christophe holds three Master's degrees in Law, European Law, and Tax Management. He is a Chartered Accountant and Tax Advisor with expertise in corporate governance. Christophe began his career as an M&A lawyer in Brussels before moving to a role as a Tax Advisor at KPMG Belgium. He later founded Financial Way, where he served as CEO and CFO for more than 15 life science startups. Passionate about wine, skiing, and tranquility, Christophe even completed a marathon and enjoys long commutes by train or bike, preferring them over driving.
IP Consultant
Koen Vanhalst holds a PhD in Biotechnology from the University of Ghent and has experience as an Examiner at the European Patent Office. He qualified as a European Patent Attorney in 2009 and a Belgian Patent Attorney in 2011, becoming a partner at De Clercq & Partners in 2017. In 2023, he earned a Certificate in Patent Litigation in Europe. Koen teaches Intellectual Property at Ghent Universityand is active in organizations like AIPPI Belgium and the Belgian Council for Intellectual Property. At Amyl, he develops IP strategy while enjoying traveland cultural exploration in his free time.
Former CSO, strategic advisor
Karine worked for over 20 years in the R&D department at GSK Vaccines, holding key positions such as Vaccine Project Leader and Head of Discovery Performance Unit at the GSK RD Center in Italy. She has a PhD in Biochemistry from Liege University, specializing in Protein Engineering. From 2021 to 2024, she served as CSO of Amyl, overseeing preclinical development. She now serves as a Strategic Advisor. Karine enjoys spending time with her family, attending classic and rock concerts, and taking trips in her van to explore nature.
Chairman, Founder
Florent Gros has has held various leadership positions in venture, intellectual property and business transactions at Nestlé, Pasteur Merieux Connaught and Novartis in Switzerland, Europe and North America. Florent has been an active investor for Novartis Venture Funds, seeding companies, serving as director and advisor, sometimes serving as ad. interim CEO, for biotech and medtech companies such as Adicet Bio, Anokion, Binx Health, Covagen, Evolva, Gensight Biologics, Inflazome, Merus, Okairos, Oculis, Vivet Therapeutics.
Merieux Equity Partners
Valérie Calenda started her career as research scientist in Hematology and Virology at the Institut National de la Recherche Médicale (INSERM). After collaborating on a French/US research program relating to HIV at Davis University, she joined Transgene S.A., an affiliated company of Institut Mérieux, focusing on gene Therapy and immunotherapy. She then led a spin-off project in cardio-vascular therapeutic area before collaborating with a Paris based seed Venture Capital firm. Valérie also managed several biotech clinical-stage product developments within the infectious diseases and oncology disease areas, from pre-IND to Phase 2. This led her to manage both in-licensing and out-licensing activities, including global license agreement and alliance management with Hoffman La Roche, acquisition of biotech assets in Europe and in the US.
Investment Manager
Helene has a PhD in molecular biology during which she studied the signaling pathways activated in response to chemotherapeutic treatments in cancer cells. She also completed a master’s degree in management. After an experience in customer support at Eurogentec, she joined the technology transfer office of the University of Liege for more than 8 years where she managed Intellectual property, negotiated collaboration and license agreements with companies and support the setting up of spin-offs. Afterwards, she joined Noshaq as a Life Sciences Investment Manager following up on several Noshaq’s holdings in biotech companies.
President
Kenneth A. Buckfire is the President and co-Founder of Miller Buckfire & Co. During his 30 year career in restructuring he has advised clients in a broad range of industries including oil & gas, oilfield services, homebuilding and real estate, merchant power, electric utilities, broadcasting, media, telephone and data services, shipping, governments and government agencies. In addition to co-founding Miller Buckf ire in 2002 (acquired by Stifel Financial in 2012), he co-founded Marblegate Asset Management in 2008 which was sold when Stifel Financial acquired Miller Buckfire in 2012.
CEO, CMO, Founder
Pierre Vandepapelière has been Amyl's co-founder, CEO, and CMO since 2020. Previously, he was CEO of Imcyse from 2014 to 2019, transforming the company into a rapidly growing biotech and raising €35M in Series B funding. During the COVID-19 pandemic, he contributed to several vaccine projects, including creating Astrivax. Pierre has also held leadership roles at Neovacs and GlaxoSmithKline. He holds a medical degree and a PhD. In his spare time, Pierre enjoys sailing, photography, and birdwatching.